
Pre-made Codrituzumab benchmark antibody ( Whole mAb, anti-GPC3 therapeutic antibody, Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-114
Pre-Made Codrituzumab biosimilar, Whole mAb, Anti-GPC3 Antibody: Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-114-1mg | 1mg | 3090 | ||
GMP-Bios-ab-114-10mg | 10mg | 21890 | ||
GMP-Bios-ab-114-100mg | 100mg | 148000 | ||
GMP-Bios-ab-114-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Codrituzumab biosimilar, Whole mAb, Anti-GPC3 Antibody: Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 therapeutic antibody |
INN Name | Codrituzumab |
Target | GPC3 |
Format | Whole mAb |
Derivation | Humanized |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2013 |
Year Recommended | 2014 |
Companies | Perseus Proteomics;Chugai Pharmaceutical;Roche |
Conditions Approved | na |
Conditions Active | Liver cancer |
Conditions Discontinued | na |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
